Quince Therapeutics (QNCX) EPS (Basic) (2018 - 2026)
Quince Therapeutics (QNCX) posted EPS (Basic) of -$12.31 for Q2 2026, down 117.12% on a QoQ basis from $71.91 in Q1 2026, and up 82.1% year-over-year from -$6.76 in Q2 2025.
Powered by 
Analysis
Quince Therapeutics (QNCX) EPS (Basic) (2018 - 2026) Analysis & Trends
Quince Therapeutics has reported EPS (Basic) for 9 years, with the latest figure at -$12.31 in Q2 2026.
- On a quarterly basis, EPS (Basic) rose 82.1% year-over-year to -$12.31 in Q2 2026; TTM through Jun 2026 was -$12.3, a 94.15% increase from a year earlier, with the FY2025 full-year figure at -$254.72, up 3.12% from the prior year.
- EPS (Basic) was -$12.31 for Q2 2026 at Quince Therapeutics, down from $71.91 in the prior quarter.
- The five-year high for EPS (Basic) was $71.91 in Q1 2026, with the low at -$143.63 in Q1 2022.
- Average EPS (Basic) over 5 years is -$53.57, with a median of -$50.84 recorded in 2025.
- The sharpest annual moves came in 2024 and 2026: EPS (Basic) tumbled 372.98% in 2024, then jumped 205.12% in 2026.
- Over 5 years, EPS (Basic) stood at -$33.04 in 2022, then slumped by 44.57% to -$47.77 in 2023, then retreated by 21.0% to -$57.8 in 2024, then sank by 33.19% to -$76.98 in 2025, then jumped by 84.01% to -$12.31 in 2026.
- The last three EPS (Basic) figures came in at -$12.31 (Q2 2026), $71.91 (Q1 2026), and -$76.98 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -0.40 |
| 10 | Quince Therapeutics | 175.52 Mn | 175.52 Mn | - | -12.31 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.31 |
| Mar 31, 2026 | 71.91 |
| Dec 31, 2025 | -76.98 |
| Sep 30, 2025 | -49.83 |
| Jun 30, 2025 | -68.75 |
| Mar 31, 2025 | -68.41 |
| Dec 31, 2024 | -57.80 |
| Sep 30, 2024 | -25.45 |
| Jun 30, 2024 | -128.68 |
| Mar 31, 2024 | -51.84 |
| Dec 31, 2023 | -47.77 |
| Sep 30, 2023 | -29.67 |
| Jun 30, 2023 | -27.21 |
| Mar 31, 2023 | -68.35 |
| Dec 31, 2022 | -33.04 |
| Sep 30, 2022 | -44.48 |
| Jun 30, 2022 | -102.04 |
| Mar 31, 2022 | -143.63 |
| Dec 31, 2021 | 447.84 |
| Sep 30, 2021 | -145.84 |